•  

Posts Tagged: proof-of-concept studies

LegWorks developing better, more affordable prosthetic knees for developing world

TORONTO (May 27, 2015)  – LegWorks Inc., backed with a $2 million blend of private and Government of Canada investments catalyzed by Grand Challenges Canada, is a new Toronto-based company that will contribute to a better life for amputees in developing countries. The LegWorks AT-knee was covered in the Toronto Star on June 1, 2015 in "Great advances being made in assistive technology" by Kate Allen and in Healio Orthotics & Prosthetics News on June 2. The LegWorks “All-Terrain Knee” (AT-Knee) is a ... Read more

Triphase signs collaboration and option agreement with Celgene Corporation, leading innovator of cancer therapies

MI portfolio company actively seeking additional products for licensing and development TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator. Triphase Accelerator's announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing. Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the ... Read more

Crowdmark to save teacher marking time and government dollars

Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots TORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others. This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub. The Crowdmark assessment interface, informed by decades ... Read more

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day. What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy? Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ... Read more